NCT02772497

3 Month Outcome of Ziv-aflibercept for DME

Three-month Outcome of Ziv-aflibercept for Diabetic Macular Edema

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Marashi Eye Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose is to show the 3-month efficacy and safety in diabetic macular edema treated with intravitreal ziv-aflibercept.

Detailed description

Multi-studies have shown that Intravitreal aflibercept (Eylea) is effective and safe in diabetic macular edema (DME) treatment and has gained FDA approval but it is expansive where ziv aflibercept (ZALTRAP) has the same molecule but with high osmilar buffer solution which is FDA approved for colon rectus cancer treatment and it is cost effective. Studies have shown that intravitreal ziv aflibercept is safe and nontoxic despite the high osmolarity and even has short term effect in wet age related macular degeneration.

Conditions

• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	Ziv aflibercept	Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks

Timeline

• Start date: 2016-01-01
• Primary completion: 2016-05-01
• Completion: 2016-05-01
• First posted: 2016-05-13
• Last updated: 2017-07-06